10 results
In the present study, we aim to perform a feasibility study to prove that 89Zirconium-bevacizumab PET scanning can indeed detect all small primary breast cancer lesions. Data from the present study may be used to design further studies with regard…
To assess the anti-tumor activity of LGX818/MEK162 in combination with third targeted agents after progression on LGX818/MEK162 combination therapy.
The primary objective of the study is to evaluate the feasibility of 89Zr-bevacizumab PET imaging as a biomarker before and during treatment with everolimus in patients with metastatic RCC. 89Zr-bevacizumab PET imaging will be regarded a promising…
The primary objective is to determine if disease associated lesions in patients with VHLD can be visualized with 89Zr-bevacizumab PET scans. Secondary objectives are to explore if 89Zr-bevacizumab PET imaging can differentiate progressive from non-…
To assess the effects of 3-month NHT on the 3-year course of PSA and testosterone in patients treated with BT for low-intermediate risk clinically localized prostate carcinoma. In addition, we would like to assess the effects of 3-month NHT on…
The two main objectives of the study are:* To assess the efficacy of ADT in treatment naïve patients with recurrent and/or metastatic, androgen receptor (AR) expressing, SGCs. The primary measure of efficacy is Progression-Free Survival (PFS).* To…
Primary ObjectiveTo determine if JNJ-56021927 plus gonadotropin releasing hormone (GnRH) agonist in subjects with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of…
The aim of this feasibility study is to validate pre-treatment [89Zr]-bevacizumab PET/CT as an imaging biomarker for prediction of treatment response to bevacizumab treatment in patients with NF2 related (vestibular) schwannomas.
Feasibility to detect a difference in uptake on 18F-FDHT scan after 4 weeks of treatment with bicalutamide in metastatic breast cancer patients.
This study aims to investigate the progression-free survival (PFS) according to RECIST 1.1 criteria on matched targeted therapy by STA-analysis (PFS2) in comparison to the PFS recorded on the therapy administered immediately prior to enrolment (PFS1…